Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Packer, Milton; D. Anker, Stefan; Butler, Javed; Filippatos, Gerasimos; Pocock, Stuart; E. Carson, Peter; L. Januzzi, James; Verma, Subodh; Tsutsui, Hiroyuki; Brueckmann, Martina; Jamal, Waheed; Kimura, Karen; Schnee, Janet; Zeller, Cordula; Cotton, Daniel; Alcides Bocchi, Edimar; Böhm, Michael; Choi, Dong‐Ju; Chopra, Vijay; Chuquiure‐Valenzuela, Eduardo; Giannetti, Nadia; Janssens, Stefan; Zhang, Jian; Ramón González‐Juanatey, José; Kaul, Sanjay; Brunner‐La Rocca, Hans‐Peter; Merkely, Béla; J. Nicholls, Stephen; V. Perrone, Sergio; L. Piña, Ileana; Ponikowski, Piotr; Sattar, Naveed; Senni, Michele; Seronde, Marie‐France; Špinar, Jindřich; Squire, Iain; Taddei, Stefano; Wanner, Christoph; Zannad, Faı̈ez

doi:10.1056/nejmoa2022190

Public

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Published in New England Journal of Medicine • Aug 28, 2020

Authors:

Milton Packer

Stefan D. Anker

Javed Butler

Abstract

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, inclu...

Subject

Empagliflozin

Heart failure

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!